Corvus Pharmaceuticals, Inc. cash flow to debt ratio of -3.50K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Corvus Pharmaceuticals, Inc.'s free cash flow has decreased 29.68% from $-25.42M last year to $-32.97M, signaling decreasing performance

Corvus Pharmaceuticals, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Corvus Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.03 last year to 0.00 today, signaling strengthened financials

Corvus Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Corvus Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Corvus Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Corvus Pharmaceuticals, Inc.'s short-term assets of $58.21M exceed its short-term liabilities of $9.38M

Corvus Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Corvus Pharmaceuticals, Inc.'s return on equity of -38.92%, is lower than 15.00%, indicating bad performance

Corvus Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Corvus Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Corvus Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Corvus Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Corvus Pharmaceuticals, Inc.'s yearly earnings has increased -75.47% since last year from $-62.29M to $-15.28M, signaling increasing performance

Corvus Pharmaceuticals, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -19.84% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Corvus Pharmaceuticals, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Corvus Pharmaceuticals, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Corvus Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Corvus Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Corvus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Corvus Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Corvus Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Corvus Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Corvus Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Corvus Pharmaceuticals, Inc. has a price-to-book ratio of 5.60x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Corvus Pharmaceuticals, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue